Bluejay Diagnostics (NASDAQ:BJDX) Issues Earnings Results

Bluejay Diagnostics (NASDAQ:BJDX) posted its quarterly earnings data on Thursday. The company reported ($1.95) earnings per share for the quarter, Zacks reports.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ:BJDX traded down $0.06 during trading on Friday, reaching $1.77. The stock had a trading volume of 8,119 shares, compared to its average volume of 17,898. Bluejay Diagnostics has a 1-year low of $1.65 and a 1-year high of $16.68. The business has a fifty day moving average price of $1.93 and a 200-day moving average price of $3.58. The stock has a market cap of $1.82 million, a PE ratio of 0.00 and a beta of 0.72.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.